IRON241220P55000
- 2.50
- 0.000.00%
Disc Medicine Newsroom
Disc Medicine Is Maintained at Buy by Stifel
Disc Medicine Analyst Ratings
Stifel Maintains Disc Medicine(IRON.US) With Buy Rating, Raises Target Price to $90
A Quick Look at Today's Ratings for Disc Medicine(IRON.US), With a Forecast Between $70 to $118
Disc Medicine (IRON) Gets a Buy From Wells Fargo
Promising Pipeline Developments Bolster Buy Rating for Disc Medicine
Scotiabank Remains a Buy on Disc Medicine (IRON)
Cantor Fitzgerald Maintains Disc Medicine(IRON.US) With Buy Rating, Raises Target Price to $99
Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Disc Medicine (IRON) and BridgeBio Pharma (BBIO)
Disc Medicine Analyst Ratings
Morgan Stanley Maintains Disc Medicine(IRON.US) With Buy Rating, Maintains Target Price $85
Douglas Tsao's Buy Rating for Disc Medicine: Promising Efficacy and Market Potential of DISC-0974 in Anemia Treatment
H.C. Wainwright Maintains Disc Medicine(IRON.US) With Buy Rating, Maintains Target Price $118
Promising Clinical Data and Strategic Advancements Drive Buy Rating for Disc Medicine
Jefferies Maintains Disc Medicine(IRON.US) With Buy Rating, Raises Target Price to $111
Disc Medicine Is Maintained at Buy by HC Wainwright & Co.
Disc Medicine Analyst Ratings
Stifel Maintains Disc Medicine(IRON.US) With Buy Rating, Maintains Target Price $79
Morgan Stanley Maintains Disc Medicine(IRON.US) With Buy Rating, Maintains Target Price $85
BMO Capital Maintains Disc Medicine(IRON.US) With Buy Rating, Maintains Target Price $112